Category: Drug Discovery
Global Drug Discovery
-
Multiple Sclerosis Drugs
... at a CAGR of 6.7% over the analysis period 2024-2030. Immmunomoderator Drugs, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$13.2 Billion by the end of ... Read More
-
Radiodermatitis
... 4.2% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$412.0 Million by the end of the analysis period. Growth in ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Anemia Drugs
... CAGR of 4.1% over the analysis period 2024-2030. Iron Deficiency Anemia, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the end of the ... Read More
-
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
... reach US$57.7 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Stimulant, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$47.7 ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
High Content Screening (HCS)
... 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$1.0 Billion by the end ... Read More
-
Peripheral Arterial Disease (PAD) Therapeutics
... Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Peripheral Stents, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.8 Billion ... Read More
-
Biosimulation Technology
... CAGR of 15.6% over the analysis period 2024-2030. Software, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$5.7 Billion by the end of the analysis period. ... Read More
-
Drug Discovery Informatics
... at a CAGR of 9.6% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$3.4 Billion by the end of ... Read More
-
Hemophilia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Hemophilia A Drugs, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$21.3 Billion by the end of the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Sterility Testing
... CAGR of 10.9% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$184.9 Million by the end of the ... Read More
-
Fragment-based Drug Discovery
... at a CAGR of 8.8% over the analysis period 2024-2030. Fragment Screening, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.1 Billion by the end of ... Read More
-
Chlamydia Infection Diagnostics and Therapeutics
... Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Diagnostics, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$1.6 Billion by ... Read More
-
Pneumonia Therapeutics
... CAGR of 6.7% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$6.8 Billion by the end of the analysis period. ... Read More
-
Veterinary Autoimmune Disease Therapeutics Global Market Report 2025
... disease therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly ... Read More
-
Botulinum Toxin
... CAGR of 8.8% over the analysis period 2024-2030. Type A, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$11.0 Billion by the end of the analysis ... Read More
-
Liver Cancer Drugs
... at a CAGR of 18.4% over the analysis period 2024-2030. Targeted Drug Therapy, one of the segments analyzed in the report, is expected to record a 18.4% CAGR and reach US$5.1 Billion by the end ... Read More
-
Migraine Drugs
... CAGR of 16.0% over the analysis period 2024-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$7.2 Billion by the end of the analysis ... Read More
-
Synthetic Biology
... CAGR of 27.9% over the analysis period 2024-2030. Oligonucleotides & Synthetic DNA, one of the segments analyzed in the report, is expected to record a 29.1% CAGR and reach US$39.5 Billion by the end of ... Read More
-
Acute Myeloid Leukemia (AML) Therapeutics
... Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2024-2030. Cytarabine, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$592.7 Million by ... Read More
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC), one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by the ... Read More
-
Epigenetics
... 18.2% over the analysis period 2024-2030. Epigenetics Kits, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth ... Read More
Research Assistance
